GcMAF Side Effects

Dr Yamamoto states GcMAF does not have side effects. Our experiences agree: GcMAF has shown no side effects of its own. That’s not surprising – your body expects to have it.

But your rebuilt immune system may in some cases give you minor secondary side effects, but larger side effects with late stages of cancer, and occasionally severe effects with autism, HIV and ME/CFS, as viruses fight back against the rebuilt immune system’s attack.

People’s reactions to a rebuilt immune system are very different – from zero, which is typical, to severe in a minority of cases.

Inside two hours GcMAF will begin to affect your immune system, and (if your immune system is at least partially active) a shot of 0.1ml or more may cause tiredness which usually lasts 3-4 hours.  You may feel better than usual for the first 2-3 weeks as the immune system wakes up.

Manifestations of the disease

We need to change our paradigm from the existing one that symptoms are directly due to the pathogen or insult to the understanding that the symptoms and in fact clinical markers are due to the immune response. So instead of believing shingles erupts or herpes erupts or cystitis symptoms erupt when our immunity is depressed, we see these eruptions as an immune activation.

Of course, if there are factors suppressing immune function then these reactions will be ineffective long term. But our routine approach of suppressing symptoms when faced with an “acute illness” is likely promoting chronic problems.

The immune response in autism

GcMAF/VDTP is produced in all higher order animals and is a glycoprotein that the body both needs and expects.  Therefore it produces no side effects in humans and any symptoms are the result of an activated immune system – the manifestation of the disease.

If possible these symptoms should be managed accordingly, any attempt to suppress them can lead to prolonged symptoms and therefore discomfort.  An extract from Dr Bradstreets paper

“During the first few weeks of treatment, 3 of 40 patients (7.5%) experienced low to moderate rise in body temperature, typically occur-ring 24 to 48 hours after the GcMAF injection and lasting less than 24 hours.  Parents were instructed to use ibuprofen only if the temperature exceeded 102° F (approximately 39°C), and two were treated during the first few weeks. By the second month, no patients experienced significant febrile events. Interestingly, during the first 3 weeks, 6 of 40 patients (15%) were observed to have rashes compatible with viral exan¬themas (generally on the trunk and in fine papules more commonly than maculae). Petechiae were not observed. These rashes could represent the manifestation of latent or persistent viral infections interacting with activated macrophages”

Fever as an immune response – good or bad?

Fever is generally measured at about 40 – 40.5c (103 – 104f) and occurs naturally when we are infected by a virus, for example.

Fever is a very effective, and wise, reaction that has developed in all mammals and humans.

Because viruses, bacteria and pathogens multiply rapidly their membranes are thinner than those of naturally occurring cells and the fever weakens the membrane which makes them more vulnerable to an immune attack, or permanently disabling them.

The rise in temperature also stimulates the white blood cells in our immune system resulting in macrophage activation. Activated macrophages will then chase down, attack, kill and engulf any invader.

Worth mentioning as a foot note is that because we are all built from the same cellular building blocks, macrophages will recycle about 95% of the virus into new immune cells (killing them to strengthen us).

The other 5% is cellular debris and will be detoxified naturally.

Toxicology studies of GcMAF

The performed pre‐clinical toxicology studies of human Gc globulin in mice, rats, guinea pigs, rabbits and Shetland ponies showed no toxic effects. In beagle dogs receiving a daily dose of 20 mg/kg Gc globulin intravenous for 14 days, clinical as well as histological immunological reactions caused by production of antibodies against human Gc globulin and immune complex formation were observed.

Future studies will hopefully show whether administration of Gc globulin to patients with severe tissue injuries such as trauma, liver failure and sepsis will be able to reduce the patient’s risk of developing hypercoagulation, shock and multiple organ failure.

Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin: Vitamin D Binding Protein – Pihl, Joergensen, Santoni-Rugiu, Leifsson, Hansen, Laursen, Houen: Basic & Clinical Pharmacology & Toxicology, 2010, Vol 107, pp 853-60.

If cancer, after the end of the first week of GcMAF you may notice the immune system has begun to attack tumours; at the end of three weeks it will be attacking at full strength, but you may not be aware of this.

The tumours should swell slightly initially as the immune system inflames and attacks them. Markers will rise initially as the tumours break up. If prostate cancer, GcMAF initially causes PSA numbers to rise for 2-3 months for the same reason.

If you are a responder, stage 4 or terminal cancer is not necessarily a bar to success.

But by comparison with chemotherapy or radiation treatments, the side effects are trivial.

There are two principal experiences here.  People with HIV either experience nothing except their symptoms disappear in around 16 weeks,  or every disease they have manifests itself for about 24 hours. In this case, for 16 weeks taking GcMAF is worse than living with HIV normally.

If HIV, the IRIS disease may cause you to get worse before you get better. We don’t do well here, because the viruses conceal themselves with biofilms and block the VDR.

It seems 70% of CFS patients simply get cured in about 18 weeks without side effects.

In 30% the diseases fight the immune system back rather as IRIS does in HIV, but not as bad. Nutrition is really important. You need the fully blown caveman diet of meat, fish vegetables and lipids. If you are on processed food, vegan, vegetarian or fast food diets, you are unlikely to make progress.

Occasionally there is initial pro-inflammatory response with worsening of asthma-like symptoms; it is the best indicator of an M1 shift. That is activation of pro-inflammatory macrophages that do the job of fighting viruses and disease. Although unwelcomed, this is the best indication that GcMAF is doing its job and it will eventually clear the body of the disease.

GcMAF is particularly good at rebuilding the liver and kidneys from stage 4 failure. Your immune system will firstly inflame and swell tumours in order to expose them, prior to destroying them. (In exposing cancers, GcMAF may reveal cancers you didn’t know you had.)  We do now regularly eradicate liver cancer (and cirrhosis too). Nutrition is vital. We have had complete successes with liver cancer where people were given only 2 months to live.

If in brain cancer you get headaches after taking GcMAF for just over a week, this may be intercranial pressure, which is serious. Treat with mannitol and diuretics  (steroids / cortizone as a last resort.) Reduce the dose to 0.05 ml. Contact us immediately – we can put you in touch with a doctor who specialises in this.

GcMAF needs 8 weeks to begin to reduce tumour mass – after that,  your symptoms should be receding.

With the above exceptions, and as a general rule of thumb, if the average participant is capable of a 40 minute brisk walk in the sunshine each day, even if they are terminal stage 4 and a high responder, they should have no difficulty surviving the war,  and typically will, at most, occasionally experience  the  symptoms of a fever – hot flushes and tiredness.

Please note these are our experiences so far; we are not doctors and you should take GcMAF under the supervision of a doctor. If at any time you feel you want to discontinue Gc MAF, please do so. We do NOT suggest you abandon any life saving treatment. If you are on rigorous medications, always confer with your specialist and ask for progress reports before making any changes to your treatment regime

If you are taking GcMAF, please check this often for new information, as new data comes in.

This Post Has 4 Comments

  1. Simon Rivett

    If I purchase gcmaf can I inject it myself or only by a doctor. If I can what is the best procedure
    Thanks simon

    1. clc

      Hello Simon,

      Thank you for the message and for your interest.
      If you were to try GcMAF you can inject it yourself, this is very easy and can be done with a diabetic needle.
      You would have to purchase these needles but they can be obtained from a chemist or through Amazon via next day delivery, it costs roughly £12 for 100 needles.
      When injecting you would inject 0.3 ml every three days, this can be injected in various places (arm, leg, thigh, bum, stomach etc).


  2. Claire

    Hello. Our doctor came across your site and referred me for my husband with late stage colon cancer. We would like to try it. He is on chemotherapy but it is not working so he will come off. He is starting to show signs of getting weaker… Sleeping a bit more and getting more pain. Please can you advise me of how we can start this treatment. We are based just outside London in England. Does he need a doctor to give injections or can we do ourselves. He has type 1.diabetes so is quite comfortable injecting, if it’s not too complicated relating to the tumour sites. What dosage should he begin with and work to? He has a lot of tumours in his liver, some in lungs, in colon etc. Thank you for your help.

    1. Banksy

      Dear Clair, thank you for your email and interest in our products. As a team of biochemists and researchers we cannot give any medical advice or recommendations, neither would it be fair on you for us to do so. But it is useful that your Doctor has referred you to us and I will endeavour to answer your questions as honestly as possible. The following information is a ‘standard reply’ but gives information and links that you and your doctor may find useful, we hope you do.

      What is GcMAF?

      Often the question arises about the molecule known as GcMAF – I hope you find the following information useful:
      In 2008-2009, four human studies appeared claiming fantastic results for a groundbreaking new cancer treatment. The studies were conducted Dr. Nabuto Yamamoto, who at the time was a Professor of Biochemistry at Temple University Medical School in Philadelphia. He was assisted by a team of other researchers.

      If the results hold up then the new treatment, a natural protein found in a healthy human body, could be one of the most exciting new cancer developments ever seen.

      In the first study, Dr. Yamamoto supplied the protein to doctors treating HIV patients resulting in complete eradication of the infection. After seven years follow-up, their blood counts remained normal.

      In another study, the Yamamoto team treated 16 non-anemic metastatic breast cancer patients with a single injection of 100 nanograms of GcMAF per week for 22 weeks.

      In the third study, all 16 non-anemic metastatic prostate patients were tumour free after 24 weeks and remained so at seven years follow-up.

      In the fourth study, all eight non-anemic metastatic colorectal patients were cancer-free after 48 weeks and remained so at seven years follow-up as confirmed by CT scans.

      In short, and astonishing as it sounds, Professor Yamamoto achieved a 100% remission rate in metastatic cancer patients.

      The discovery didn’t happen overnight. It was the product of years of research at a respected mainstream medical institution.
      The pioneering work of Dr Yamamoto
      The foundations of GcMAF began in 1979 when Dr. Yamamoto started basic research in molecular biology and immunology. Each insight obtained in one study became the driving force for the design of the next.

      These building blocks of knowledge grew until they formed a huge infrastructure that became his basis for a new theory about how cancer occurs and how it could be treated.

      The first publication in a peer-reviewed journal on GcMAF appeared in 1994. Dr. Yamamoto and colleagues at Temple University demonstrated that GcMAF activated macrophages. These are vital immune cells that kill pathogens and cancer cells and switch on other aspects of the immune system.

      A year later he showed that a defect in the production of GcMAF inside the body contributes to a poorer immune response in AIDS patients. In 1996 he demonstrated that this was also the case in cancer patients.
      What is GcMAF and how does it work?
      Professor Yamamoto discovered that cancer cells and some viruses, but not normal cells, secrete an enzyme called alpha-N-acetyl-galactosaminidase (Nagalase).

      This enzyme is able to block the production of a protein that activates macrophages to attack the cancer cells. He named this Gc-protein-derived Macrophage Activating Factor, GcMAF for short.

      Certain immune cells, T and B lymphocytes, make GcMAF from its precursor, vitamin D-transport protein (Gc protein). This protein has three sugars attached to the 420th amino acid along its 458 amino acid chain. The removal of two of these sugars by enzymes produced by the lymphocytes turns Gc protein into GcMAF.

      The enzyme released by cancer cells and some viruses, nagalase, removes some sugars from Gc protein, thereby preventing its conversion to GcMAF and rendering the patients’ immune system deficient. The sugar-removing process is called deglycosylation.

      Nagalase’s ability to inhibit macrophage activation can be bypassed by using GcMAF. The treatment restores normal immunity and the body is then able to attack tumour cells.

      Professor Yamamoto demonstrated that when macrophages are activated by GcMAF their efficacy increases by 30-fold. There is also a 15-fold rise in superoxide ions. These also attack pathogens and cancer cells.

      GcMAF is least likely to work in patients who have a large tumour burden and in those whose tumours are well differentiated (i.e. look similar to normal cells). It works best in those with a low tumour load and in poorly differentiated (highly abnormal) cells.

      GcMAF can be stopped from working by opiates and steroids or patients lacking sufficient red blood cells.

      Dr. Yamamoto’s subjects had undergone conventional therapies to reduce the tumour burden to a very low level. They were also at an early stage of metastasis and had no conditions that could block the protein.
      Other anticancer effects of GcMAF
      Until 2002 it was believed GcMAF activated only macrophages. Then Professor Yamamoto, together with researchers from Japan, discovered that GcMAF has direct anti-angiogenic effects on endothelial cells. (Angiogenesis is the process whereby cancer tumours form their own network of blood vessels.)

      This finding was confirmed the following year by the highly distinguished doctor Judah Folkman and others at Children’s Hospital in Boston.

      For one factor to both activate the immune system and anti-angiogenesis is remarkable, but the good news doesn’t stop there.

      In 2010, researchers from the University of Kentucky showed for the first time that GcMAF directly inhibits the migration, proliferation and metastatic potential of human prostate cancer cells. This happened independently of macrophage activation.

      And in 2012 the Kentucky discovery was confirmed in breast cancer cells, thanks to the efforts of Marco Ruggiero, a professor of molecular biology, working with a team at the University of Florence, Italy.

      But what was more extraordinary, the Italian researchers demonstrated a reversal of breast cancer cells to their neoplastic phenotype. In other words, GcMAF reverted cancer cells back to normal cells.

      They also published a study in 2011 demonstrating that GcMAF can counter the potentially carcinogenic effects of cadmium in human breast cancer cells.

      Protein extraction & purification
      Our partner laboratory is ISO & GMP registered, and one of the leading protein specialist laboratories in Europe. The protein found in our Vitamin D Transport Protein (VDTP) products is the precursor (natural source) to GcMAF, this means VDTP activates more immune cell types (Lymphocytes, T & B Cells and variants of) before converting to GcMAF in the body and activating the Macrophage immune cell.

      Protein extraction, purification and conversion is a 34-step process that includes full activity and sterility assays which we publish on our website.
      Our Autism research initiatives
      Since 2014 we have supported 1000’s of families with autism and have some of the results published here:



      Some research papers that demonstrate multi-faceted functionality of GcMAF

      Cancer research papers

      Immuntherapy for Prostate Cancer with Gc Protein-Derived Macrophage Activating Factor
      16 nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.
      Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto: GcMAF, Translational Oncologie: Vol 1, No 2: 65-72 (2008a)

      Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)
      Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.
      Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima: International Journal of Cancer 122: 461-467 (2008b)

      Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF
      After 32–50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.
      Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima:

      Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.
      On the effects of GcMAF in human breast cancer cells in vitro. GcMAF reverts the neoplastic phenotype; cancer cells become normal and are deprived of their metastatic potential.
      Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Anticancer Res. 2012 Jan;32(1):45-52.

      A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.
      GcMAF activates macrophages that attack and destroy human breast cancer cells. The molecular assembly and mode of action of GcMAF are elucidated. For the first time an interconnection with the vitamin D receptor (VDR) signalling is presented.
      Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S. Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.

      Gc protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.
      On the therapeutic effects of GcMAF in 20 patients with advanced cancer defined as incurable. Clinical cases of breast, prostate, bladder, ovarian, colon, tongue, larynx, head and neck carcinomas, lymphomas and oligodedroglioma
      Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. OncoImmunology 2013; 2:e25769; http://dx.doi.org/10.4161/onci.25769.

      Multifaceted immunotherapeutic effects of vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells.
      On the multifaceted effects of GcMAF in human breast cancer cells and human neuroblastoma (a brain tumour) cells. Here it is demonstrated that when GcMAF is prepared according to its molecular configuration, it is 100 fold more effective than “regular” GcMAF in destroying human cancer cells.
      Ruggiero M, Pacini S, Morucci G, Branca J, Ward E, Smith RJ, Thyer L and Gulisano M (2013). Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00221.

      Effects of vitamin D binding protein-derived macrophage activating factor on human neuroblastoma cells and predicted molecular interaction with the vitamin D receptor.
      These results are consistent with the hypothesis that the known anticancer efficacy of DBP-MAF can be ascribed to different biological properties of the molecule that include inhibition of tumour-induced angiogenesis and direct inhibition of cancer cell proliferation, migration and metastatic potential.
      M. Ruggiero, M.G. Fiore, S. Magherini, G. Morucci, J.J.V. Branca, M. Gulisano, L. Thyer, S. Pacini. Abstr.

      Alpha‐N‐acetylgalactosaminidase levels in cancer patients are affected by Vitamin D binding protein‐derived macrophage activating factor.
      GcMAF has a significant therapeutic effect in 20 patients with advanced cancer. These results are presented at the 67th National Congress of the Italian Society of Anatomy and Histology.
      Gulisano M, Pacini S, Thyer L, Morucci G, Branca JJV, Smith R, Wards E and Noakes D. (P85). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S104.

      Other potential therapeutic effects of GcMAF

      Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin d analogs in the prevention of cardiovascular diseases.
      GcMAF increases energy production at the mitochondrial level. These results explain the reported increase of energy observed by patients treated with GcMAF for different diseases.
      Pacini S, Morucci G, Branca JJ, Aterini S, Amato M, Gulisano M, Ruggiero M. Nutrients. 2013 Jun 7;5(6):2076-92. doi: 10.3390/nu5062076.

      Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.
      On the therapeutic effects of GcMAF in patients with cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis. This is the first report on the therapeutic effects of GcMAF in patients with these dreadful neurological diseases.
      Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini. DOI : 10.3844/ajisp.2013.78.84. American Journal of Immunology. Volume 9, Issue 3

      Initial Observations of elevated Alpha-n-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections.
      On the therapeutic effects of GcMAF in autism. Autism is eradicated in a significant percentage of cases. About 85% of subjects show improvement following GcMAF treatment.
      James Jeffrey Bradstreet, emar Vogelaar and Lynda Thyer. Autism Insights 2012:4 31–38. doi: 10.4137/AUI.S10485.

      Immuntherapy of HIV-Infected Patients with Gc Protein-Derived Macrophage Activating Factor (GcMAF)
      Since latently HIV-infected cells are unstable and constantly release HIV virions, the activated macrophages rapidly intercept the released HIV virions to prevent reinfection resulting in exhaustion of infected cells. After less than 18 weekly administrations of 100 ng GcMAF for nonanemic patients, they exhibited low serum Nagalase activities equivalent to healthy controls, indicating eradication of HIV-infection, which was also confirmed by no infectious center formation by provirus inducing agent-treated patient PBMCs. No recurrence occurred and their healthy CD + cell counts were maintained for 7 years.
      Nobuto Yamamoto, Naofumi Ushijima, Yoshihiko Koga: Journal of Medical Virology 81:16–26 (2009)

      Vitamin D binding protein-derived macrophage activating factor stimulates proliferation and signalling in a human neuronal cell line.
      The effects of GcMAF on human neurons explain its therapeutic effects in autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis.
      Morucci G, Fiore MG, Magherini S, Branca JJV, Gulisano M, Thyer L, Ruggiero M and Pacini S.

      Treatment and Prevention of Cadmium-induced alterations on human neurons.
      GcMAF has a neuro-protective effect against heavy metal-induced neuronal damage. Implications for autism and chronic fatigue syndrome treatment.
      Morucci G, Branca JJV, Ruggiero M, Gulisano M and Pacini S. (P29). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.

      Effects of GcMAF on human neurons and ME/CFS treatment.
      GcMAF is able to increase the viability and the metabolism of human neurons, and, most important, to induce neurons to establish contact with each other. As it is well known in the field of neurosciences, a decreased connectivity among neuronal circuits is at the basis of most, if not all, neurological and neurodevelopmental disorders. The paper also explains why GcMAF combats pain.

      Toxicology studies of GcMAF

      Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin: Vitamin D Binding Protein
      The performed pre‐clinical toxicology studies of human Gc globulin in mice, rats, guinea pigs, rabbits and Shetland ponies showed no toxic effects. In beagle dogs receiving a daily dose of 20 mg/kg Gc globulin intravenous for 14 days, clinical as well as histological immunological reactions caused by production of antibodies against human Gc globulin and immune complex formation were observed.
      Future studies will hopefully show whether administration of Gc globulin to patients with severe tissue injuries such as trauma, liver failure and sepsis will be able to reduce the patient’s risk of developing hypercoagulation, shock and multiple organ failure.
      Pihl, Joergensen, Santoni-Rugiu, Leifsson, Hansen, Laursen, Houen: Basic & Clinical Pharmacology & Toxicology, 2010, Vol 107, pp 853-60.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.